APLS Stock Recent News
APLS LATEST HEADLINES
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of intravitreal pegcetacoplan for the treatment of geographic atrophy (GA).
Apellis (APLS) rises 3.3% as the treatment of GA patients with Syfovre demonstrates a visual function benefit in a prespecified endpoint at month 36 in a late-stage, long-term extension study.
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?
WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET.
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
WALTHAM, Mass. and STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced positive one-year results from the Phase 2 NOBLE study investigating systemic pegcetacoplan, a targeted C3 therapy, for the treatment of post-transplant recurrence of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). These data were presented during a late-breaking oral presentation at the European Renal Association (ERA) Congress taking place May 23-26 in Stockholm, Sweden.
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.54 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.56 per share a year ago.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) is down nearly 40% versus its year-to-date high but a Mizuho analyst does not see it as an opportunity to buy per se. Mizuho remains ‘neutral' on Apellis Pharmaceuticals stock Graig Suvannavejh reiterated his “neutral” stance on the biotech stock in a recent research note.
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.